object
describ
pathogenesi
clinic
present
cerebrospin
fluid
find
outcom
aspergillu
mening
meningoenceph
arachnoid
method
case
aspergillu
mening
describ
comprehens
review
englishlanguag
literatur
conduct
identifi
report
case
aspergillu
mening
describ
januari
decemb
result
ninetythre
case
includ
one
describ
herein
aspergillu
mening
identifi
fiftytwo
individu
without
predispos
factor
known
caus
immunosuppress
acut
chronic
mening
diagnos
patient
meningoenceph
remain
present
spinal
arachnoid
ventricul
cerebrospin
fluid
cultur
aspergillu
spp
posit
case
galactomannan
antigen
test
diagnosi
life
achiev
patient
case
fatal
rate
overal
case
fatal
rate
conclus
aspergillu
mening
may
occur
immunocompet
immunocompromis
patient
run
acut
chronic
cours
find
systemat
review
extend
inform
lifethreaten
infect
could
assist
physician
achiev
improv
outcom
british
infect
associ
publish
elsevi
ltd
right
reserv
central
nervou
system
cn
infect
well
recogn
manifest
dissemin
aspergillosi
observ
immunocompromis
patient
mortal
rate
greater
contrast
aspergillu
mening
seldomli
encount
clinic
entiti
found
frequent
immunocompet
rather
immunocompromis
host
inform
aspergillu
mening
limit
spars
knowledg
review
topic
publish
far
present
case
aspergillu
mening
along
review
publish
case
sinc
case
report
aspergillu
mening
meningoenceph
arachnoid
ventricul
well
seri
cn
aspergillosi
identifi
search
pubm
scopu
databas
english
literatur
refer
list
review
addit
case
research
conduct
year
use
research
term
includ
aspergillu
mening
cerebr
aspergillosi
central
nervou
system
aspergillosi
aspergillu
arachnoid
mycot
mening
purpos
review
case
mening
meningoenceph
caus
aspergillu
spp
defin
life
follow
cerebrospin
cultur
posit
aspergillu
spp
togeth
mening
encephal
syndrom
presenc
galactomannan
antigen
aspergillu
dna
detect
polymeras
chain
reaction
pcr
test
csf
togeth
mening
syndrom
postmortem
diagnos
aspergillu
mening
includ
autopsi
clearli
indic
involv
mening
pictur
mening
microscop
identif
aspergillu
hypha
posit
aspergillu
cultur
inflamm
involv
spinal
leptomening
case
classifi
spinal
arachnoid
patient
consid
immunocompromis
follow
condit
met
hivaid
infect
solid
organ
transplant
hematolog
diseas
without
bone
marrow
transplant
autoimmun
diseas
treat
steroid
immunosuppress
drug
diabet
mellitu
condit
treat
corticosteroid
immunosuppress
drug
man
refer
infecti
diseas
ward
februari
neurosurgeri
unit
diagnosi
aspergillu
mening
made
fig
clinic
histori
notabl
heroin
intraven
drug
abus
high
alcohol
intak
untreat
chronic
hepat
c
methadon
mainten
therapi
mg
day
one
month
admit
intern
medicin
ward
anoth
hospit
investig
natur
low
back
pain
headach
low
grade
fever
c
appear
month
earlier
magnet
reson
imag
mri
brain
neg
parenchim
mening
lesion
contrari
mri
lumbar
spine
show
abnorm
contrast
enhanc
spinal
canal
suggest
intradur
mass
lesion
condit
traction
effect
root
cauda
equina
colordoppl
echocardiogram
show
mild
mitral
regurgit
blood
urin
cultur
neg
well
serolog
test
hiv
cerebrospin
fluid
csf
analysi
perform
februari
shown
fig
gram
ziehlneelsen
stain
well
bacteri
mycobacteri
cultur
neg
search
bacteri
cryptococcu
neoforman
antigen
cerebrospin
cultur
grew
aspergillu
flavu
suscept
amphotericin
b
voriconazol
posaconazol
itraconazol
caspofungin
aspergillu
galactomannan
antigengm
platelia
aspergillu
sanofi
diagnost
pasteur
marnela
coquett
franc
detect
csf
blood
higher
index
valu
former
respect
upon
admiss
ward
februari
patient
fever
c
alert
complain
frontal
headach
photophobia
without
neck
stiff
intraven
treatment
voriconazol
start
mgkg
everi
h
load
dose
follow
mgkg
togeth
ceftriaxon
g
two
week
later
control
brain
spinal
mri
show
mening
enhanc
cystern
distribut
especi
prepontin
area
around
basilar
arteri
togeth
endocanalar
patholog
enhanc
fig
b
concomit
csf
analysi
show
reduct
wbc
pmn
improv
glucos
level
mgdl
serum
mgdl
strike
increas
protein
level
mgdl
wherea
time
point
csf
cultur
turn
neg
gm
index
csf
peripher
blood
persist
fever
headach
worsen
radiolog
pictur
caspofungin
mg
load
dose
mg
mainten
dose
ad
antifung
regimen
discontinu
antibiot
therapi
voriconazol
blood
csf
trough
concentr
obtain
week
therapi
similar
mgl
respect
therapeut
drug
monitor
arrang
day
later
show
toxic
concentr
drug
prompt
dosag
adjust
despit
absenc
clinic
biochem
sign
voriconazol
toxic
anoth
csf
examin
perform
march
disclos
improv
paramet
fig
repeat
mri
brain
spine
march
show
reduct
pial
cystern
contrast
enhanc
progress
endocanalar
inflamm
involv
segment
new
evalu
neurosurgeri
consult
deem
procedur
unfeas
patient
discharg
receiv
day
voriconazol
therapi
total
cumul
dosag
mg
one
month
caspofungin
total
cumul
mg
patient
left
mainten
therapi
oral
voriconazol
dosag
mg
due
rais
alt
level
ul
appear
visual
disturb
persist
elev
trough
voriconazol
concentr
mgl
end
april
patient
readmit
hospit
ward
persist
abnorm
liver
function
test
result
visual
disturb
requir
discontinu
voriconazol
substitut
intraven
liposom
amphotericin
b
lamb
mgday
complain
persist
low
back
pain
irradi
lower
extrem
preserv
deep
tendon
superfici
reflex
repeat
attempt
obtain
csf
sampl
lumbar
punctur
unsuccess
nerv
conduct
electromyographi
studi
show
mild
sensorimotor
bilater
demyelin
polyneuropathi
new
mri
brain
spine
perform
may
substanti
unchang
therapi
lamb
gm
evalu
weekli
show
valu
rang
patient
drug
addict
histori
decid
resum
oral
voriconazol
therapi
sinc
posit
perman
intraven
devic
lamb
infus
outpati
basi
judg
riski
dosag
mg
everi
h
start
june
show
week
trough
peak
concentr
mgl
respect
new
mri
brain
spine
perform
august
demonstr
reduct
pial
enhanc
along
cervic
tract
conu
medullari
cauda
equina
mild
volumetr
reduct
endocanalar
lumbar
abscess
clinic
patient
well
orient
posit
bilater
la
egu
sign
neurolog
examin
discharg
subsequ
lost
followup
detail
chronolog
order
summari
case
aspergillu
mening
chronic
meningitispachymening
meningoenceph
arachnoid
ventricul
includ
one
present
herein
case
shown
tabl
women
men
median
age
year
rang
year
diagnosi
made
life
patient
autopsi
patient
diagnosi
obtain
frequent
life
among
immunocompet
patient
comparison
immunocompromis
individu
tabl
almost
half
case
n
z
aspergillu
identifi
histolog
cultur
without
speciat
infect
caus
fumigatu
n
z
flavu
n
z
terreu
n
z
oryza
granulosu
candidu
identifi
one
case
fortyon
patient
consid
immunocompromis
host
aid
patient
autoimmun
diseas
treat
steroid
solid
organ
transplant
recipi
hematolog
patient
undergo
chemotherapi
bone
marrow
transplant
subject
steroid
therapi
chronic
obstruct
pulmonari
diseas
copd
sever
acut
respiratori
syndrom
patient
diabet
final
cush
diseas
sarcoidosi
fiftytwo
patient
without
classic
risk
factor
invas
aspergillosi
central
nervou
system
involv
presum
result
direct
extens
aspergillu
orbit
ear
paranas
sinus
patient
iatrogen
direct
inocul
aspergillu
spinal
anesthesia
patient
neurosurgeri
patient
epidur
steroid
inject
patient
six
intraven
drug
abus
infect
probabl
acquir
hematogen
rout
among
remain
subject
predispos
factor
could
identifi
six
patient
one
patient
notabl
presenc
follow
pregnanc
alcohol
abus
fungal
endocard
near
drown
common
syndrom
acut
mening
observ
patient
follow
meningoenceph
n
z
chronic
cours
mening
observ
patient
five
patient
show
pictur
spinal
arachnoid
case
associ
mening
ventricul
tabl
acut
cours
character
rapid
deterior
clinic
pictur
usual
end
death
observ
among
immunocompromis
host
patient
direct
inocul
fungu
cerebrospin
fluid
subarachnoid
space
contrast
subacut
chronic
form
mening
go
unrecogn
sever
week
sometim
display
relaps
charact
frequent
present
among
immunocompet
patient
intraven
drug
abus
patient
diabet
howev
latter
clinic
pictur
also
observ
among
sever
patient
undergon
neurosurgeri
cerebrospin
fluid
cultur
posit
aspergillu
spp
case
slightli
higher
preval
among
immunocompet
oppos
immunocompromis
host
tabl
nine
patient
aspergillu
spp
cultur
csf
repeat
attempt
median
number
lumbar
punctur
rang
antigenbas
assay
employ
fifteen
patient
gm
antigen
use
platelia
elisa
patient
unspecifi
assay
patient
pastorex
assay
patient
individu
gm
antigen
detect
csf
specimen
immunocompet
patient
immunocompromis
host
assess
overal
sensit
median
csf
gm
index
rang
serum
gm
concomitantli
measur
case
turn
posit
patient
csf
gm
serial
determin
median
show
good
correl
patient
receiv
least
one
dose
antifung
agent
die
interv
time
rang
day
year
patient
chronic
mening
initi
treat
antibiot
also
receiv
antitubercular
therapi
overal
casefat
rate
cfr
observ
signific
differ
immunocompet
oppos
immunocompromis
patient
patient
autopsi
avail
case
method
diagnosi
made
patient
twelv
case
basilar
mening
identifi
spinal
cord
involv
observ
patient
presenc
mycot
aneur
involv
either
intern
carotid
arteri
basilar
arteri
shown
patient
concomit
subarachnoid
hemorrhag
transtentori
tonsillar
uncal
herniat
present
three
patient
review
literatur
mukoyama
et
al
report
case
aspergillosi
involv
cn
mening
meningoenceph
howev
aspergillu
isol
fail
cultur
cerebrospin
fluid
specimen
clinicalpatholog
studi
central
nervou
system
aspergillosi
patient
sign
mening
irrit
life
autopsi
mening
focal
affect
nearli
half
case
present
seri
regard
patient
pictur
pure
mening
observ
case
meningoenceph
diagnos
patient
patient
diagnosi
mening
fever
headach
common
present
symptom
follow
neck
stiff
pr
oppos
immunocompromis
individu
differ
might
explain
aggress
acut
cours
diseas
observ
immunosuppress
host
culturebas
diagnosi
aspergillu
mening
hamper
lack
sensit
shown
posit
result
observ
review
publish
case
pr
previous
suggest
minimum
ml
cerebrospin
fluid
cultur
mycosi
suspect
repeat
cultur
larg
volum
csf
critic
success
vitro
isol
howev
larg
volum
easi
obtain
clinic
practic
hand
serial
lumbar
punctur
inde
seem
role
sinc
case
fungu
could
success
isol
cerebrospin
fluid
sever
attempt
noncultur
base
diagnost
method
diagnosi
aspergillosi
employ
csf
fifteen
patient
seem
outperform
tradit
cultur
overal
sensit
although
cutoff
valu
gm
index
yet
formal
establish
diagnosi
cn
aspergillosi
propos
might
lower
use
serum
sampl
due
lower
background
reactiv
csf
median
csf
gm
index
seri
valu
higher
usual
observ
serum
well
cutoff
two
serial
serum
determin
use
among
immunocompromis
patient
valu
singl
determin
employ
nonhematolog
patient
notabl
serum
csf
gm
screen
concomitantli
neg
result
observ
three
case
serum
index
valu
alway
higher
csf
serum
although
serial
determin
csf
avail
three
case
may
provid
use
inform
therapeut
respons
final
seem
platelia
gm
test
work
well
irrespect
speci
aspergillu
involv
shown
case
describ
verveij
mole
fumigatu
candidu
flavu
respect
cultur
csf
review
show
aspergillu
mening
omin
prognosi
global
casefat
rate
cfr
much
better
outcom
among
immucompet
patient
cfr
observ
versu
cfr
regist
among
immunocompromis
patient
data
slightli
better
cfr
report
lin
et
al
literaturebas
survey
publish
infecti
diseas
societi
america
idsa
guidelin
recommend
voriconazol
treatment
central
nervou
system
aspergillosi
recommend
mainli
base
upon
studi
regard
patient
hematolog
disord
specif
mention
treatment
aspergillu
mening
present
review
encompass
long
period
time
introduct
voriconazol
ie
patient
treat
amphotericin
b
dehoxychol
less
receiv
voriconazol
time
diseas
pr
recent
analysi
conduct
schwartz
et
al
case
cn
aspergillosi
respons
rate
median
surviv
day
among
patient
treat
voriconazol
shown
voriconazol
show
excel
penetr
cn
demonstr
studi
conduct
healthi
guinea
pig
high
cerebrospin
fluid
plasma
ratio
togeth
rapid
penetr
across
blood
brain
barrier
observ
includ
present
report
determin
cerebrospin
fluid
concentr
voriconazol
avail
four
case
report
valu
rang
mgl
csfplasma
ratio
rang
hope
recent
propos
busi
clinic
set
voriconazol
therapeut
drug
monitor
tdm
obtain
end
day
subsequ
first
week
therapi
associ
poor
outcom
voriconazol
concentr
initi
observ
pascual
cowork
addit
miyaki
et
al
recent
show
increas
risk
death
among
patient
invas
mycos
treat
voriconazol
initi
trough
concentr
less
mgl
contrast
sever
studi
expert
opinion
suggest
optim
maximum
voriconazol
concentr
exceed
mgl
anoth
crucial
issu
yet
address
far
optim
length
antifung
therapi
patient
aspergillu
mening
well
cerebr
aspergillosi
patient
antifung
treatment
administ
month
employ
voriconazol
lose
patient
followup
uncertain
long
would
necessari
continu
specif
treatment
analysi
literatur
regard
patient
aspergillu
mening
treat
voriconazol
show
differ
length
treatment
rang
week
month
howev
point
case
outcom
follow
drug
discontinu
report
long
term
durat
voriconazol
treatment
patient
aspergillu
mening
cn
involv
matter
efficaci
also
toxic
regard
risk
phototox
risk
induc
squamou
cell
carcinoma
mention
caspofungin
employ
patient
combin
voriconazol
role
singl
agent
treatment
aspergillu
mening
hamper
lack
signific
penetr
across
bloodebrain
barrier
drug
except
one
appar
success
case
flucytosin
use
associ
amfb
role
treatment
aspergillosi
remain
anecdot
conclus
review
show
aspergillu
mening
rare
clinic
entiti
much
frequent
observ
among
immunocompet
patient
character
csf
neutrophil
pleocytosi
case
hypoglycorrhachia
case
cultur
csf
posit
one
third
case
gm
antigen
test
use
sensit
reach
although
data
show
poor
prognosi
believ
widespread
use
diagnost
method
greater
sensit
ie
pcr
gm
togeth
avail
voriconazol
therapi
may
allow
improv
outcom
provid
diagnosi
achiev
earlier
optim
length
antifung
therapi
howev
remain
determin
particular
fund
receiv
support
work
